A Long-Term Safety Study of MT-4666 in Patients With Mild to Moderate Alzheimer's Disease (AD)
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2015
At a glance
- Drugs Encenicline (Primary) ; Acetylcholinesterase inhibitors
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 29 Sep 2015 Planned End Date changed from 1 Jan 2017 to 1 Oct 2015 as ClinicalTrials.gov record.
- 29 Sep 2015 Planned primary completion date changed from 1 Jan 2017 to 1 Oct 2015 as per ClinicalTrials.gov record.
- 05 Jan 2015 New trial record